<style face="normal" font="default" size="100%">1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)</style>

Drupal-HighWire